<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606785</url>
  </required_header>
  <id_info>
    <org_study_id>IGRG00033.01</org_study_id>
    <nct_id>NCT03606785</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Single Dose Tranexamic Acid in Reducing Blood Loss During Colorectal Cancer Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 46 patients scheduled for explorative laparotomy with the aim of radical debulking
      surgery for colorectal cancer will be randomized into two equal groups one will receive
      tranexamic acid and one placebo.

      The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over
      20 minutes after induction of anesthesia and before surgical incision. In the control group,
      patients will receive a placebo of 100 mL 0.9% normal saline. The primary endpoint is
      reduction in blood loss, while the secondary endpoint was the number of patients needing
      transfusion and occurrence of postoperative thrombotic complications (myocardial infarction,
      stroke, pulmonary embolism, renal failure, or bowel infarction) within 30 days after surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2018</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in blood loss</measure>
    <time_frame>1 month</time_frame>
    <description>Blood loss will be calculated (volume estimated as the blood remaining in sponges and drapes and the volume in suction bottles during surgery).The amount of drained blood will be measured in 1st 24 hours.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Colorectal Surgery</condition>
  <arm_group>
    <arm_group_label>tranexamic acid group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injection</intervention_name>
    <description>The TA group will receive an intravenous bolus of (10 mg/kg) in 100 ml of normal saline over 20 minutes after induction of anesthesia and before surgical incision</description>
    <arm_group_label>tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo injection</intervention_name>
    <description>patients will receive a placebo of 100 mL 0.9% normal saline</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  ASA 1 and ASA 2 patients scheduled for colorectal cancer surgery.

          -  Age above 18 years &amp; less than 65 years.

        Exclusion criteria:

          -  Thrombophilia or any bleeding disorder.

          -  Previous or active thromboembolic disease.

          -  Family history of thromboembolism.

          -  Known Allergy to TA.

          -  Liver dysfunction.

          -  Preexisting renal dysfunction (serum creatinine &gt;1.2 mg/dL).

          -  Coronary stent insertion within a year prior to operation.

          -  Cardiovascular problem (e.g., myocardial infarction, atrial fibrillation, angina,
             heart failure),

          -  Lifelong warfarin therapy for thromboembolism prophylaxis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed Othman, MD</last_name>
    <phone>00201005098394</phone>
    <email>ahmadhothman@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>NCI, Cairo university</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekramy Mansour, MD</last_name>
      <phone>00201224642810</phone>
      <email>ekrameymansoure@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>January 11, 2020</last_update_submitted>
  <last_update_submitted_qc>January 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Ahmed H Othman</investigator_full_name>
    <investigator_title>Assisstant professor of Anesthesia ICU and pain Relief</investigator_title>
  </responsible_party>
  <keyword>colorectal,blood, transfusion,haemorrhage,tranexamic acid.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

